Hepatotoxicity following vincristine therapy.
Cancer
; 54(9): 2006-8, 1984 Nov 01.
Article
en En
| MEDLINE
| ID: mdl-6090004
ABSTRACT
A patient is reported with small cell lung cancer treated with combination chemotherapy (cyclophosphamide, vincristine and etoposide [VP-16-213] who developed transient liver function abnormalities secondary to vincristine therapy. Serum transaminase (SGOT and SGPT) levels rose by 2 to 6 times, lactic dehydrogenase (LDH) 1.5 to 2 times, and alkaline phosphatase and gamma-glutamyl transpeptidase (GGTP) 1.5 to 2 times normal. Enzyme abnormalities were observed by the 6th day following drug administration and returned to normal between 16 and 48 days, except for the GGTP elevations which persisted longer. Vincristine has been suspected to cause liver damage and to enhance radiation-induced hepatic injury. The authors report this case of moderate transient transaminitis confirmed by rechallenge with vincristine.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vincristina
/
Enfermedad Hepática Inducida por Sustancias y Drogas
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Cancer
Año:
1984
Tipo del documento:
Article